9 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
is required for two segment operations: 1) diagnostic R&D and 2) laboratory services.
Segment Information
The Company is organized in two operating … segments, Diagnostic Research and Development (R&D) and Laboratory Services, whereby its chief operating decision maker (“CODM”) assesses the performance
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
segment operations: 1) diagnostic R&D and 2) laboratory services.
Segment Information
The Company is organized in two operating segments, Diagnostic … Research and Development (R&D) and Laboratory Services, whereby its chief operating decision maker (“CODM”) assesses the performance of and allocates
8-K
EX-99.1
BIAF
BioAffinity Technologies Inc
15 May 24
Results of Operations and Financial Condition
6:07pm
for additional research personnel and higher R&D laboratory supply costs.
Clinical development expenses were $49,000 for the first quarter of 2024
POS AM
le9 rif1x
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-99.2
ahajlz4nad7ykbm797
10 Oct 23
Regulation FD Disclosure
5:27pm
8-K
EX-99.1
60s59x
15 May 23
Results of Operations and Financial Condition
12:22pm
- Prev
- 1
- Next